The CSL share price is currently trading 16.7% below its all-time high of $342.75. As we have seen recently, many quality shares that have been sold-off can surge in an unstoppable rally on the turn of a dime.

With the CSL share price consolidating, is now the time to buy shares in the biotech giant before its too late?

Why is the CSL share price not at all-time highs?

The fact that CSL is trading below its all-time highs could reflect portfolio rotation among many investors. With the broader market performing stronger than expected, many investors will be opting to take their profits and sell blue-chips like CSL. By freeing up capital, investors can then load their portfolio with more beaten-down laggards and other cyclical shares.

In addition to portfolio rotation, some investors might be selling their CSL shares as the company faces rising collection costs during the coronavirus pandemic.

How has CSL performed during the pandemic?

Although CSL is not actively participating in the race to develop a vaccine for COVID-19, the biotech giant is working to develop potential therapies by collecting plasma from recovered patients. In conjunction with other global biotech companies, CSL has launched a campaign in the US encouraging recovered COVID-19 patients to donate plasma. CSL is also collecting recovered donor plasma in Australia, with the company partnering with the Australian Red Cross Lifeblood Service.

There have been some concerns that the global shutdowns as a result of the pandemic may result in a supply shortage in plasma collection. In addition, CSL has the obligation to ensure the safety of its donors by undertaking various disinfecting and screening protocols, which could impact margins.  

Bullish broker note

Earlier this month, analysts from broker UBS released a bullish note on CSL and slapped a $342 12-month price target on the company. Analysts flagged a 15% decline in plasma collection volume for the April–June period, however volumes are expected to recover as US states move to ease regulations. Researchers from the broker continue to see CSL as the preferred option in the health sector based on the company’s robust product pipeline and low level of gearing.

Should you buy?

In my experience, the fear of missing out, especially in unprecedented times such as this, can cloud the decision making of the most experienced investor. However, in the case of a quality company such as CSL, the decision should be straightforward. This market darling has a strong capital position with more than $1 billion in available liquidity and has also reaffirmed its profit guidance for FY20.

If portfolio rotation is the cause for a drop in CSL’s share price, I think that it won’t be sustained for too long and buyers should flood in again. For more cautious investors it may be prudent to wait until August when CSL reports its full-year results to get a better picture of where the company stands.

More reading

• Top brokers name 3 ASX 200 shares to buy today
• Where to invest $5,000 into ASX 200 shares immediately
• Is the CSL share price in the buy zone?
• 3 companies with great intangible asset moats
• Why CSL, Harvey Norman, IPH, & Saracen shares are charging higher

Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Should you buy CSL shares before it’s too late? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3cRsJQZ

The big four banks have all tumbled lower today after they followed the lead of their U.S. counterparts.

The worst performer in the group has been the Westpac Banking Corp (ASX: WBC) share price.

The shares of Australia’s oldest bank were down as much as 6% at one stage. They have since recovered somewhat, but are still down almost 4% to $17.80 at the time of writing.

Why is the Westpac share price sinking lower?

As well as getting caught up in a selloff which has been triggered by concerns over a potential second wave of COVID-19 in the United States, an update by Westpac could be adding to the selling pressure.

Earlier today, Westpac provided an update on its dealings with AUSTRAC. This is in relation to the civil proceedings the agency launched against the bank in November. This was for the alleged contraventions of its obligations under the Anti-Money Laundering and Counter-Terrorism Financing Act.

According to the release, Westpac has continued to review its processes and as part of that has disclosed to AUSTRAC issues regarding its obligation to file threshold transaction reports.

In addition to this, a month after the civil proceedings were launched, as part of Westpac’s lookback announced in its response to AUSTRAC’s claim, Westpac reported additional suspicious matter reports (SMRs) in relation to potential child exploitation.

This morning the bank revealed that AUSTRAC is further investigating these matters and has advised that it may amend its statement of claim to include allegations arising from these investigations.

AUSTRAC has requested further information from the bank on these matters. This includes the details of 272 of its customers, many of whom were subject to SMRs previously.

A further case management hearing is scheduled for next week. Management intends to provide further updates on the matter when appropriate.

More reading

• ASX 200 down 2.2%: Westpac tumbles, TPG reveals special dividend plans
• Why Jumbo, Santos, Westpac, & Zip Co shares are crashing lower
• ASX 200: improved consumer sentiment to near pre COVID-19 levels
• ASX 200 drops 3%, Webjet share price sinks
• What today’s ASX 200 selloff tells me

Motley Fool contributor James Mickleboro owns shares of Westpac Banking. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Westpac share price lower on AUSTRAC update appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2UCPguB

The Mach7 Technologies Ltd (ASX: M7T) share price is one of the few shining lights on the market today as investors react to an acquisition.

Mach7 is a global provider of enterprise image management systems for the healthcare sector. The company’s solutions are designed to accelerate diagnosis and care delivery, reduce costs, and significantly improve patient outcomes.

Mach7 shares have been stuck in a trading halt since Wednesday while the company completed a capital raising to fund a new acquisition.

And it appears investors are viewing these moves favourably seeing as though Mach7 is one of the only ASX growth shares not being heavily punished today. In fact, at the time of writing, Mach7 shares are actually charging 7.60% higher.

Why has the Mach7 share price avoided today’s sell-off?

This morning, Mach7 announced it has completed the institutional component of its capital raising. This comprised a $3.7 million placement and $19.7 million entitlement offer, raising a total of $23.4 million. These funds were raised at an offer price of 68 cents per share, which was a 13.9% discount to Mach7’s last trading price of 79 cents.

Funds raised from the capital raising, together with the company’s existing cash reserves, will be used to fund the acquisition of Client Outlook.

Client Outlook is a leading provider of an enterprise image viewing technology called eUnity. It has around 100 customers across North America and Asia and generated $8.8 million of revenue in FY20.

Following the completion of the acquisition, Mach7 will be a complete front and back-end enterprise imaging solution provider. The acquisition also provides the company with a departmental clinical diagnostics PACS (picture archive communication system) solution offering – expanding Mach7’s addressable market from US$0.75 billion to US$2.75 billion.

Highlighting further benefits, Mach7 stated that the acquisition will increase the company’s sales pipeline by around 50%, with $40 million of contracted revenue opportunities in the near term. 

What’s more, Mach7’s customer install base will increase by around 200% from 51 to approximately 150 customers. Contracted annual recurring revenue also stands to benefit, increasing by 70% to $14.75 million.

Mach7 believes this is a low-risk acquisition since the two companies have an established partnership, reselling each other’s product. As such, Client Outlook is a well-known entity, team and product to Mach7 and deep technology integration has already been completed.

The purchase price has been set at CA$38.5 million (~A$40.8 million). Mach7 will have approximately $15 million cash reserves post acquisition, which is expected to be completed by 10 July 2020.

“This deal is truly transformational for Mach7 and its shareholders,” said Mike Lampron, CEO of Mach7. 

“This offering is extremely compelling, but the enterprise-first philosophy of Mach7 and Client Outlook is truly what I believe is going to set us apart as we move forward together,” Mr Lampron added.

More reading

• Why Mach7, Meridian, Spark, & TPG Telecom are pushing higher

Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of MACH7 FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Mach7 share price charges 7% higher on acquisition news appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/30yf7aQ